Head-to-head evidence
Evinacumab vs NNC0491-6075
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: ANGPTL3 · full Atherosclerotic Cardiovascular Disease pipeline
Evinacumab · Evkeeza
Marketed by Regeneron Pharmaceuticals
NCT03399786 · Phase 3 · completed
The trial randomized 65 participants to evinacumab or placebo and masked participants, care providers, investigators, and outcome assessors. Its primary LDL-C endpoint was statistically significantly improved with evinacumab, but LDL-C is a surrogate laboratory endpoint rather than a hard clinical or endoscopic measure.
NNC0491-6075
Developed by Novo Nordisk
NCT05979428 · Phase 1 · completed
Participants were randomly assigned to drug or placebo under quadruple-blind conditions across ascending-dose cohorts, a sound early-safety design, but the primary measure was the number of adverse events rather than a clinical or lipid outcome, and results have not yet been reported.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Evinacumab's landscape · NNC0491-6075's landscape